Navigation Links
Cardium Reports Non-Healing Wounds Continue to Challenge Patients and Healthcare Providers
Date:8/27/2009

diabetic person than in the general population. Among the patients with lower extremity amputation procedures, 5% to 17% will die during the operation and 2% to 30% will die within 30 days of surgery. Longer term survival is even worse. Mortality following amputation ranges from 13% to 40% at one year, 35% to 65% at 3 years and 39% to 80% at 5 years. These mortality rates are similar or worse than many common types of cancer including prostate, breast, colon and Hodgkin's disease. Despite these grim statistics, many remain unaware of the very serious nature of non-healing lower extremity ulcers in diabetic patients.

Innovative Advanced Care DNA-Based Therapy

Cardium's Excellarate(TM) product candidate is a collagen-based topical gel employing Tissue Repair Company's (TRC's) Gene Activated Matrix(TM) that is designed to locally stimulate the release of platelet-derived growth factor-B protein (PDGF-B), an important key in the human body's wound healing process. Sustained, localized micro-release of PDGF-B by a patient's own cells directly at the wound site is believed to stimulate angiogenesis and granulation tissue formation through the recruitment and proliferation of cells such as monocytes, fibroblasts and endothelial cells. These cell types are critical for the effective stimulation of a variety of wound healing processes.

Excellarate is an advanced care DNA-based biologic product candidate that is being developed to provide physicians and patients with a potentially simpler, easy-to-use treatment as compared to current therapies. Based on the positive data from a Phase1/2 study, the Company believes that the Excellarate topical gel provides a unique opportunity to: (1) improve patient compliance, based on a one or two physician administered treatment regimen, instead of current therapies which require multiple treatments by physicians or patients on a daily or weekly basis for up
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study
2. Cardium Announces Completion of Patient Recruitment in Phase 2b Clinical Trial of Excellarate(TM) for the Potential Treatment of Diabetic Foot Ulcers
3. Cardium Reports on Applicability of Corgentin to Stem Cell Therapies: Independent Studies Indicate that Ad5IGF-1 Potentiates Stem Cells to Improve Cardiac Function After Heart Attack
4. Cardiums InnerCool Announces Positive Benefits of Cooling During Robotic-Assisted Prostate Surgery Published in Urology
5. Cardium Reports on Second Quarter 2008 Highlights and Financial Results
6. Cardium Announces Appointment of Paul A. Foster, M.D. to Lead Generx and Excellarate Late-Stage Development Activities
7. Cardiums Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack
8. Cardium and Tissue Repair Companys Excellarate Candidate for Healing Diabetic Wounds Gains Media Focus in Multiple Regions Across U.S.
9. Wyoming Department of Healths Pay-for-Participation Program Reports Positive Clinical Outcomes
10. Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009
11. Nektar Therapeutics Reports Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... NEW YORK and LONDON ... in global orthopedic industry are expected to grow at ... consumption in terms of value and volume. Hip, knee ... the developed world while in emerging economies they have ... failure rates are challenging the use of composites. Non-metallic ...
(Date:12/24/2014)... KENNEWICK, Wash. , Dec. 23, 2014 /PRNewswire/ ... stage development company engaged primarily in the development ... and therapeutic applications, today announced that it has ... the Food and Drug Administration ("FDA") for marketing ... to Section 513(f)(2) of the U.S. Food, Drug ...
(Date:12/24/2014)... LEXINGTON, Mass. , Dec. 23, 2014 /PRNewswire/ ... GEVA ), a biopharmaceutical company developing therapeutic products ... European Medicines Agency (EMA) of the Marketing Authorization ... The EMA recently granted the company,s request for ... the EMA,s regulatory review time.   ...
Breaking Medicine Technology:Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3
... by Nobel laureate Paul Greengard, Medical Director of The Michael ... Dr. Jennifer L. Warner-Schmidt in New York and colleagues in ... the brain protein called p11 could lead pharmaceutical companies to ... rather than the weeks or even months required by current ...
... 23 Since 1993, when the PLCO trial was started, ... anticipation, as have others. The initial report of the results ... trial -- published last week in the New England Journal ... , * The studies offer conflicting evidence about the possibility ...
Cached Medicine Technology:Key Protein May Lead to Faster Acting Anti-Depression Drugs 2A Joint Statement From America's Prostate Cancer Advocacy, Education, and Support Organizations 2A Joint Statement From America's Prostate Cancer Advocacy, Education, and Support Organizations 3
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. ... on a "fountain of youth" drug that can delay the ... a new study suggests. Seniors received a significant boost ... a genetic signaling pathway linked to aging and immune function, ... The experimental medication, a version of the drug rapamycin, improved ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 Residents ... Retirement Community, recently showed their generous spirit by ... the Catawba County Parenting Network- Grandparents Raising Grandchildren ... children gathered around the largest Christmas tree on ... presents purchased by residents of the Abernethy Village ...
(Date:12/24/2014)... (PRWEB) December 25, 2014 Epigenetics finds ... science research, including oncology, drug discovery, developmental biology, and ... emerging as one of the most widely used techniques ... to GLOBOCAN, the prevalence of cancer is rapidly growing ... cases, 8.2 million cancer deaths, and 32.6 million people ...
(Date:12/24/2014)... (PRWEB) December 24, 2014 Dr. Vu ... the expansion of his practice and med-spa with the ... practice’s growing list of cosmetic treatments and services. , ... into the skin,” says Dr. Ho. “As a result ... such as wrinkles, sun spots, discolorations or blemishes.” , ...
(Date:12/24/2014)... Mike Billings , PT, MS, CEEAA, President ... PT, MBA, GCS, Director of Professional Development to discuss ... of the Improving Medicare Post-Acute Care Transformation Act ... the Infinicast, the two leaders discuss how the IMPACT ... to standardize post-acute assessment data for quality, payment, and ...
Breaking Medicine News(10 mins):Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Retirement Community Residents Make Impact During Holiday Season 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 3Health News:Dr. Vu Ho Expands Facial Plastic Surgery Practice to Include New Skin Care Treatment 2Health News:Latest Episode of Infinicast Features Infinity Rehab President Discussing IMPACT Act of 2014 and Changes for Post-Acute Therapy Providers in 2015 2
... A new study says that those who suffer from ... blood clots//. ,Earlier studies had found a ... were unaware about the relationship between infections and clotting ... Scientist. ,Researcher Liam Smeeth at the London ...
... is displeased with the way the head of the North Coast ... They said that he has denied telling the Coraki community about ... the community staged a protest against the head of the North ... felt like mushrooms and wanted answers about the Health Department's plans ...
... response to less sales of butter and cheese in Canada, ... 1.7 percent//. This is due to raise in health ... "It should start stabilizing over the next few months. Retail ... absorbed by the market. It means culling cows because we ...
... study conducted by psychologists from Sheffield University most women ... women's attitudes towards sex revealed that women of all ... relationship is wrong. ,The women community despite ... stands do so out of desperation or drunkenness. The ...
... A new study has found that the peels of fruits ... source of potent antioxidants//. So it's better to have a ... those peels that fights against aging and keeps you young. ... foods containing antioxidants have soared in the United States to ...
... Organization (WHO) has called for more funds to combat the ... lives of millions of people at risk in Sudan//. ... at the earliest, the incidence and prevalence of these deadly ... Currently, Sudan is dependent on other nations to help ease ...
Cached Medicine News:Health News:WHO: Lives At Risk In Sudan As Diseases Soar, Call for Funding 2
RM-1970 Mucotome ergonomic design with E-Type coupling, designed for mucosal repair surgery....
RM-1900 Dermatome developed for reconstructive plastic surgery with E-Type coupling. Dermatome with 50 mm cutting width....
... The New Model C Dermatome - reaching ... switch - Push forward to operate in the ... mode. Autoclavable - the entire instrument and hose ... - Cut grafts in 2-, 3-, or 4-inch ...
A finely parallel striated (scratched) clear plastic membrane encapsulated between glass plates....
Medicine Products: